other material
confidence high
sentiment positive
materiality 0.60
Barinthus Biotherapeutics (fka Vaccitech) begins trading under BRNS, presents Phase 2 HBV data
Barinthus Biotherapeutics plc.
- Company renamed to Barinthus Biotherapeutics; Nasdaq ticker changes from VACC to BRNS effective Nov 7, 2023.
- Phase 2 hepatitis B trial data for VTP-300 to be presented at AASLD Liver Meeting Nov 10-14, including combination with imdusiran.
- Shareholders approved resolutions authorizing directors to allot shares up to £1,928 nominal and disapply pre-emption rights.
- Strategic shift from vaccines to T cell immunotherapies targeting chronic infectious diseases, autoimmunity, and cancer.
- Clinical collaboration with Arbutus Biopharma highlighted in late-breaking abstract on VTP-300 plus imdusiran.